Skip to main content
Premium Trial:

Request an Annual Quote

Cadus Technologies Awarded US Patent

Premium
Cadus Technologies has been awarded US Patent 7,361,498, “Yeast cells expressing modified G proteins and methods of use therefore.”
 
The inventors listed on the patent are Dana Fowlkes, James Broach, John Manfredi, Jeremy Paul, Joshua Trueheart, Christine Klein, and Andrew Murphy.
 
According to its abstract, the patent pertains to novel yeast cells that are useful for the expression of heterologous G protein coupled receptors. The yeast cells can be used in assays to screen for modulators of GPCRs. Specifically, the patent describes novel yeast cells that express a heterologous GPCR and mutant and/or chimeric G protein subunit molecules that functionally integrate the heterologous GPCR into the pheromone signaling pathway of the yeast cell. The patent also provides for the expression of heterologous GPCRs that are functionally integrated into the yeast cell membrane using a yeast α-factor leader sequence. Drug discovery assays using these yeast cells are also described.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.